Updated:
eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001828522, and its reported...
Overview
eFFECTOR Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001828522, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-03-26, it reported annual revenue of USD 0; net income of USD -35,811,000; total assets of USD 20,544,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.
Company overview
- Legal name
- eFFECTOR Therapeutics, Inc.
- Former names in filing history
- Locust Walk Acquisition Corp. (2020-11-04 to 2021-08-25)
- Classification
- Company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Solana Beach, CA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001828522
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2023USD | $0 | -$35.8M | $20.5M | $14.9M | -$29.6M | |
| FY2022USD | $3.6M | -$22.7M | $29.1M | $8.7M | -$25.9M | |
| FY2021USD | $1.4M | $15.8M | $54.1M | $49.7M | -$24.9M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| DEF 14A | DEF 14A | ||
| 8-K | 8-K | ||
| 10-K | 10-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research eFFECTOR Therapeutics, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.